Ferriprox® (deferiprone)


This site is intended for Healthcare Professionals outside the U.S.	Site for U.S. Residents

Anderson LJ. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003;361:182-4.
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516-20.
Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal 2001;22:2171-9.
Berdoukas VA, Lindeman R, Eagle C, Bohane TD, Tobias VH, de Silva K et al. Liver Assessment in a group of transfusion dependent patients treated with deferiprone and compared to a group of patients treated with desferrioxamine. Blood 94[10], 30b. 11-15-1999.
Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR et al. Evaluation of the Effects of Treatment. Survivial and Causes of Death. The 8th international Conference on Thalassemia and Hemoglobinopathies . 2001.
Ref Type: Abstract
Borgna-Pignatti, Caterina, Maria Domenica Cappellini, Piero De Stefano, Giovanni Carlo Del Vecchio, Gian Luca Forni, Maria Rita Gamberini, Roberta Ghilardi, Antonio Piga, Maria Antonietta Romeo, Huaqing Zhao, and Avital Cnaan. Cardiac morbidity and mortality in deferoximine or deferiprone treated patients with thalassemia major. Blood. 2006; 107: 3733-3737.
Callea. F. Iron chelation with oral deferiprone in patients with thalassemia [letter]. N.Engl.J.Med. 339 (23):1710-1711, 1998.
Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118(1):330-6.
Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos
G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in
patients with beta-thalassaemia major. BJH. 2006 Aug;134(4):438-44.
Galia M, Midiri M, Bartolotta V, Morabito A, Rizzo M, Mangiagli A et al. Potential Myocardial Iron Content Evaluation by Magnetic Resonance Imaging in Thalassemia Major Patients Treated with Deferoxamine or Deferiprone During a Randomized Multicenter Prospective Clinical Study. Hemoglobin 2003;27(2):63-76.
Hoffbrand AV, Al-Refaie FN, Davis B, Siritanakatkul N, Jackson BFA, Cochrane J et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91(1):295-300.
Kontoghiorghes G, Aldouri M, Sheppard L and Hoffbrand A. 1,2-dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987; 1(8545):1294-1295.
Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001 August;138(2):130-8.
Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002;28(2):196-208.
Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339(7):417-23.
Olivieri NF, Brittenham GM, Armstrong SAM, Basran RK, Daneman R, Daneman N et al. First Prospective Randomized Trial of the Iron Chelators Deferiprone (L1) and Deferoxamine. Blood 86[10 Suppl. 1], 249a. 1995.
Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in ß-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 2003;70:392-7.
Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A,
Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassaemia major patients with asymptomatic myocardial siderosis. Blood. 2006; 107:3738-3744
Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88(5):489-96.
Piga A., Facello S., Gaglioti C., Pucci A., Pietribiasi F., and Zimmermann A. No progression of liver fibrosis in thalassemia major during deferiprone or desferrioxomine iron chelation. Blood 92: 1998. (Abstract)
Richardson DR. Deferiprone: greater efficacy at depleting myocardial than hepatic iron? Lancet 2002;360:501-2.
Tanner M.A. , R. Galanello, C. Dessi, A.A. Westwood, G.C. Smith, S.V. Nair, L.J. Anderson, J.M. Walker, D.J. Pennell. Myocardial Iron Loading in Patients with Thalassemia Major on Deferoxamine Chelation. Journal of Cardiovascular Magnetic Resonance (2006) 8, 543-547
Tanner M.A. , MRCP; R. Galanello, C. Dessi, G.C. Smith, M.A. Westwood, A. Agus, M. Roughton, R. Assomull, S.V. Nair, J.M. Walker, D.J. Pennell. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance. Circulation, Journal of the American Heart Association April 2007, Vol 115, No 13
Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou
E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M,
Angastiniotis M. Survival of medically treated Thalassaemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006 Sep;91(9):1187-92.
Töndury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998 June;101(3):413-5.
Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E and Cohen A. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100(5):1566-1569.

Home

Links